Abstract
Etanercept is an anti-TNF drug with marked efficacy in inflammatory arthritis. This review addresses dermatological side effects that have been encountered in our 85 patients on the drug for rheumatoid arthritis, and reviews other reported cutaneous adverse events. Injection site reactions are common and usually self-limiting. We and others have encountered patients with recall site reactions where the four rotated injection sites simultaneously develop a hypersensitivity reaction. In all cases, the rash has responded to antihistamines and the etanercept was thereby continued. Other injection site reactions include discoid lupus and cutaneous vasculitis that respond to cessation of treatment and appropriate therapy. Skin reactions more distant from the injection site are also reviewed, with erythema nodosum, widespread lupus rashes, infections and skin tumours summarised. A patient who developed a purpuric rash at the site of last injection with a drug induced worsening of thrombocytopaenia is described. Although the therapeutic advantages of etanercept outweigh the side effects, clinicians need to be aware of the adverse reactions of these drugs with their increasing use.
Keywords: Etanercept, injection site reactions, recall reactions, lupus, erythema nodosum, purpura
Current Drug Safety
Title: Adverse Dermatological Reactions in Rheumatoid Arthritis Patients Treated with Etanercept, an Anti-TNFα Drug
Volume: 1 Issue: 3
Author(s): Shyra Rajakulendran and Chris Deighton
Affiliation:
Keywords: Etanercept, injection site reactions, recall reactions, lupus, erythema nodosum, purpura
Abstract: Etanercept is an anti-TNF drug with marked efficacy in inflammatory arthritis. This review addresses dermatological side effects that have been encountered in our 85 patients on the drug for rheumatoid arthritis, and reviews other reported cutaneous adverse events. Injection site reactions are common and usually self-limiting. We and others have encountered patients with recall site reactions where the four rotated injection sites simultaneously develop a hypersensitivity reaction. In all cases, the rash has responded to antihistamines and the etanercept was thereby continued. Other injection site reactions include discoid lupus and cutaneous vasculitis that respond to cessation of treatment and appropriate therapy. Skin reactions more distant from the injection site are also reviewed, with erythema nodosum, widespread lupus rashes, infections and skin tumours summarised. A patient who developed a purpuric rash at the site of last injection with a drug induced worsening of thrombocytopaenia is described. Although the therapeutic advantages of etanercept outweigh the side effects, clinicians need to be aware of the adverse reactions of these drugs with their increasing use.
Export Options
About this article
Cite this article as:
Rajakulendran Shyra and Deighton Chris, Adverse Dermatological Reactions in Rheumatoid Arthritis Patients Treated with Etanercept, an Anti-TNFα Drug, Current Drug Safety 2006; 1 (3) . https://dx.doi.org/10.2174/157488606777934495
DOI https://dx.doi.org/10.2174/157488606777934495 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurotuberculosis: An Overview
Central Nervous System Agents in Medicinal Chemistry Bacterial Zinc Proteases and their Inhibition
Current Enzyme Inhibition Human Parvovirus B19: An Infectious Agent with the Potential to Induce and Trigger Rheumatic Disease
Current Rheumatology Reviews Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry RNA Sensors as a Mechanism of Innate Immune Evasion among SARSCoV2, HIV and Nipah Viruses
Current Protein & Peptide Science The Protective Effects of Levosimendan on Ischemia/Reperfusion Injury and Apoptosis
Recent Patents on Cardiovascular Drug Discovery Management of Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Current Immunology Reviews (Discontinued) Recent Insights into COVID-19 in Children and Clinical Recommendations
Current Pediatric Reviews Novel Agents Targeting Nitric Oxide
Current Vascular Pharmacology Understanding the Role of Aldose Reductase in Ocular Inflammation
Current Molecular Medicine Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Clinical Relevance of Cytokines and Inflammatory Molecules in Rheumatoid Vasculitis
Current Rheumatology Reviews Polymorphisms in TOLL-Like Receptor Genes and their Roles in Allergic Asthma and Atopy
Recent Patents on Inflammation & Allergy Drug Discovery Long Chain n-3 Polyunsaturated Fatty Acids in the Prevention of Allergic and Cardiovascular Disease
Current Pharmaceutical Design Crosslinked, Polymerized, and PEG-Conjugated Hemoglobin-Based Oxygen Carriers: Clinical Safety and Efficacy of Recent and Current Products
Current Drug Discovery Technologies Cocaine and HIV-1 Interplay in CNS: Cellular and Molecular Mechanisms
Current HIV Research Anti-Interleukin-6 Receptor Antibody Therapy in Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets A Very Rare Cerebral Complication of Chemotherapy in a Young Girl: A Difficult Diagnosis
Current Drug Safety Steroid Induced Bilateral Avascular Necrosis of Head of Femur in an Adult Male Patient - A Case Report
Current Drug Safety Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets